Answers are grounded in this paper and cite their sources.
No AccessPerspectives on Hearing and Hearing Disorders: Research and DiagnosticsArticle1 Sep 2005Audiological Monitoring of Patients Receiving Ototoxic Drugs Dawn Konrad-Martin, Jane S. Gordon, Kelly M. Reavis, Debra J. Wilmington, Wendy J. Helt and Stephen A. Fausti Dawn Konrad-Martin Veterans Affairs Rehabilitation Research and Development Service, National Center for Rehabilitative Auditory Research, VA Medical CenterPortland, OR Department of Otolaryngology, Oregon Health & Science UniversityPortland, OR Google Scholar , Jane S. Gordon Veterans Affairs Rehabilitation Research and Development Service, National Center for Rehabilitative Auditory Research, VA Medical CenterPortland, OR Google Scholar , Kelly M. Reavis Veterans Affairs Rehabilitation Research and Development Service, National Center for Rehabilitative Auditory Research, VA Medical CenterPortland, OR Google Scholar , Debra J. Wilmington Veterans Affairs Rehabilitation Research and Development Service, National Center for Rehabilitative Auditory Research, VA Medical CenterPortland, OR Google Scholar , Wendy J. Helt Veterans Affairs Rehabilitation Research and Development Service, National Center for Rehabilitative Auditory Research, VA Medical CenterPortland, OR Google Scholar and Stephen A. Fausti Veterans Affairs Rehabilitation Research and Development Service, National Center for Rehabilitative Auditory Research, VA Medical CenterPortland, OR Department of Otolaryngology, Oregon Health & Science UniversityPortland, OR Google Scholar https://doi.org/10.1044/hhd9.1.17 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationTrack Citations ShareFacebookTwitterLinked In References ASHA. (1994). Guidelines for the audiologic management of individuals receiving cochleotoxic drugtherapy.Asha, 36 (Suppl. 12), 11–19. Google Scholar ASHA. (2004). Ototoxic drugs can damage hearing. Retrieved July 5, 2005, from www.asha.org/about/news/tipsheets/ototoxic Google Scholar Barron, S. E., & Daigneault, E. A. (1987). Effect of cisplatin on haircell morphology and lateral wall Na, K-ATPase activity.Hearing Research, 26, 131–137. Google Scholar Beattie, R. C., Kenworthy, O. T., & Luna, C.A. (2003). Immediate and short-term reliability of distortion-product otoacoustic emissions.International Journal of Audiology, 42, 348–354. CrossrefMedlineGoogle Scholar Bertolini, P., Lassalle, M., Mercier, G., Raquin, M. A., Izzi, G., Corradini, N., & Hartmann, O. (2004). Platinum compound-related ototoxicity in children: Long-term follow-up reveals continuous worsening of hearing loss.Journal of Pediatric Hematology/Oncology, 26, 649–655. CrossrefGoogle Scholar Black, F. O., & Pesznecker, S. C. (1993). Vestibularototoxicity. Clinical considerations.Otolaryngologic Clinics of North America, 26, 713–736. Google Scholar Blakley, B. W., & Myers, S. F. (1993). Patterns of hearing loss resulting from cis-platinum therapy.Otolaryngology–Head and Neck Surgery, 109, 385–391. Google Scholar Blakley, B. W., Gupta, A. K.,Myers, S.F., & Schwan, S. (1994). Risk factors for ototoxicity due to cisplatin.Archives of Otolaryngology–Head and Neck Surgery, 120, 541–546. Google Scholar Brown, J. J., Brummett, R. E., Fox, K .E., & Bendrick, T. W. (1980). Combined effects of noise and kanamycin. Cochlear pathology and pharmacology.Archives of Otolaryngology, 106, 744–750. Google Scholar Brummett, R. E. (1980). Drug-induced ototoxicity.Drugs, 19, 412–428. Google Scholar Brummett, R. E., & Fox, K. E. (1982). Studiesof aminoglycoside ototoxicity in animal models.In A. Whelton & H .C. Neu (Eds.), The Aminoglycosides (pp. 419–451). New York: Marcel Dekker. Google Scholar Burk, M. H., & Wiley, T. L. (2004). Continuous versus pulsed tones in audiometry.American Journal of Audiology, 13, 54–61. LinkGoogle Scholar DeLauretis, A., DeCapua, B., Barbieri, M. T., Bellussi, L., & Passali, D. (1999). ABR evaluation of ototoxicity in cancer patients receiving cisplatin or carboplatin.Scandinavian Audiology, 28, 139–143. Google Scholar Durrant, J. D., Rodgers, G., Meyers, E. N., & Johnson, J. T. (1990). Hearing loss-risk factor for cisplatin ototoxicity? Observations.American Journal of Otology, 11, 375–377. Google Scholar Fausti, S. A., Helt, W. J., Phillips, D. S., Gordon, J. S., Bratt, G. W., Sugiura, K. M., & Noffsinger, D. (2003). Early detection of ototoxicity using 1/6th octavesteps.Journalofthe AmericanAcademyof Audiology, 14, 444–450. Google Scholar Fausti, S. A., Henry, J. A., Helt, W. J., Phillips, D. S., Frey, R. H., Noff-singer, D., Larson, V. D., & Fowler, C. G. (1999). An individualized, sensitive frequency rangefor early detection of ototoxicity.Ear & Hearing, 20, 497–505. Google Scholar Fausti, S. A., Henry, J. A., Schaffer, H. I., Olson, D. J., Frey, R. H., & Bagby, G.C. (1993). High-frequency monitoring for early detection of cisplatin ototoxicity.Archives of Otolaryngology Head & Neck Surgery, 119, 661–665. Google Scholar Fausti, S. A., Henry, J. A., Schaffer, H. I., Olson, D. J., Frey, R. H., & McDonald, W. J. (1992). Early detection of aminoglycoside ototoxicity by high-frequency (³ 8 kHz) auditory evaluation.Journal of Infectious Disease, 165, 1026–1032. Google Scholar Forge, A., & Schacht, J. (2000). Aminoglycoside antibiotics.Audiology & Neuro-otology, 5, 3–22. Google Scholar Franklin, D. J., McCoy, M. J., Martin, G. K., & Lonsbury-Martin, B. L. (1992). Test/retest reliability of distortion-product and transiently evoked otoacoustic emissions.Ear and Hearing, 13, 417–429. Google Scholar Gordon, J. S., Phillips, D., Helt, W. J., Konrad-Martin, D., & Fausti, S. A. (inpress). Evaluation of insert earphones for high-frequency bedside ototoxicity monitoring.Journal of Rehabilitation Research & Development. Google Scholar Hodges, A. V., & Lonsbury-Martin, B. L. (1998). Hearing management.In P. A. Sullivan & A. M. Guilford (Eds.), Best practices in oncology management: Focus on swallowing and communication disorders (pp. 269–290). San Diego, CA: Singular Press. Google Scholar Lonsbury-Martin, B. L., & Martin, G. K. (2001). Evoked otoacoustic emissions as objective screeners for ototoxicity.Seminars in Hearing, 22, 377–391. CrossrefGoogle Scholar Roede, J., Harris, F. P., Probst, R., & Xu, L. (1993). Repeatability of distortion product otoacoustic emissions in normally hearing humans.Audiology, 32, 273–281. Google Scholar Rougier, F., Claude, D., Maurin, M., Sedoglavic, A., Ducher, M., Corvaisier, S., Jelliffe, R., & Maire, P. (2003). Aminglycoside nephrotoxicity:Modeling,simulation,and control.Antimicrobial Agents & Chemotherapy, 47, 1010–1016. Google Scholar Simpson, T. H., Schwan, S. A., & Rintelmann, W. F. (1992). Audiometric test criteria in the detection of cisplatin ototoxicity.Journal of the American Academy of Audiology, 3, 176–185. Google Scholar Stavroulaki, P., Apostolopoulos, N., Segas, J., Tsakanikos, M., & Adamopoulos, G. (2001). Evoked otoacoustic emissions—An approach for monitoring cisplatin induced ototoxicity in children.International Journal of Pediatric Otorhinolaryngology, 59, 47–57. Google Scholar Additional Resources FiguresReferencesRelatedDetailsCited ByThe ASHA Leader24:10 (54-59)1 Oct 2019Embedded Ear Care: Audiology on the Cancer Treatment TeamAmy Custer Volume 9Issue 1September 2005Pages: 17-22 Get Permissions Add to your Mendeley library History Published in issue: Sep 1, 2005 Metrics Downloaded 54 times Topicsasha-topicsleader-topicsasha-article-typesasha-sigsCopyright & Permissions© 2005 American Speech-Language-Hearing AssociationPDF DownloadLoading ...
No takes yet. Share an insight, caveat, or question.
Konrad‐Martin et al. (2005) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: